Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes
- PMID: 16140943
- DOI: 10.1158/0008-5472.CAN-05-0858
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes
Abstract
Brother of the Regulator of Imprinted Sites (BORIS) is a mammalian CTCF paralog with the same central 11Zn fingers (11ZF) that mediate specific interactions with varying approximately 50-bp target sites. Regulated in vivo occupancy of such sites may yield structurally and functionally distinct CTCF/DNA complexes involved in various aspects of gene regulation, including epigenetic control of gene imprinting and X chromosome inactivation. The latter functions are mediated by meCpG-sensitive 11ZF binding. Because CTCF is normally present in all somatic cells, whereas BORIS is active only in CTCF- and 5-methylcytosine-deficient adult male germ cells, switching DNA occupancy from CTCF to BORIS was suggested to regulate site specificity and timing of epigenetic reprogramming. In addition to 11ZF-binding paternal imprinting control regions, cancer-testis gene promoters also undergo remethylation during CTCF/BORIS switching in germ cells. Only promoters of cancer testis genes are normally silenced in all somatic cells but activated during spermatogenesis when demethylated in BORIS-positive germ cells and are found aberrantly derepressed in various tumors. We show here that BORIS is also expressed in multiple cancers and is thus itself a cancer-testis gene and that conditional expression of BORIS in normal fibroblasts activates cancer-testis genes selectively. We tested if replacement of CTCF by BORIS on regulatory DNA occurs in vivo on activation of a prototype cancer-testis gene, MAGE-A1. Transition from a hypermethylated/silenced to a hypomethylated/activated status induced in normal cells by 5-aza-2'-deoxycytidine (5-azadC) was mimicked by conditional input of BORIS and is associated with complete switching from CTCF to BORIS occupancy at a single 11ZF target. This site manifested a novel type of CTCF/BORIS 11ZF binding insensitive to CpG methylation. Whereas 5-azadC induction of BORIS takes only few hours, derepression of MAGE-A1 occurred 1 to 2 days later, suggesting that BORIS mediates cancer-testis gene activation by 5-azadC. Indeed, infection of normal fibroblasts with anti-BORIS short hairpin RNA retroviruses before treatment with 5-azadC blocked reactivation of MAGE-A1. We suggest that BORIS is likely tethering epigenetic machinery to a novel class of CTCF/BORIS 11ZF target sequences that mediate induction of cancer-testis genes.
Similar articles
-
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.Cancer Res. 2005 Sep 1;65(17):7763-74. doi: 10.1158/0008-5472.CAN-05-0823. Cancer Res. 2005. PMID: 16140944
-
Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.Int J Cancer. 2008 Feb 15;122(4):777-84. doi: 10.1002/ijc.23140. Int J Cancer. 2008. PMID: 17957795
-
Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.Nucleic Acids Res. 2007;35(21):7372-88. doi: 10.1093/nar/gkm896. Epub 2007 Oct 25. Nucleic Acids Res. 2007. PMID: 17962299 Free PMC article.
-
BORIS in human cancers -- a review.Eur J Cancer. 2012 Apr;48(6):929-35. doi: 10.1016/j.ejca.2011.09.009. Epub 2011 Oct 21. Eur J Cancer. 2012. PMID: 22019212 Review.
-
The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.Semin Cancer Biol. 2002 Oct;12(5):399-414. doi: 10.1016/s1044-579x(02)00060-3. Semin Cancer Biol. 2002. PMID: 12191639 Review.
Cited by
-
Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines.Cell Oncol (Dordr). 2013 Oct;36(5):351-62. doi: 10.1007/s13402-013-0140-x. Epub 2013 Jul 18. Cell Oncol (Dordr). 2013. PMID: 23864224
-
Expression of the epigenetic factor BORIS (CTCFL) in the human genome.J Transl Med. 2011 Dec 14;9:213. doi: 10.1186/1479-5876-9-213. J Transl Med. 2011. PMID: 22168535 Free PMC article. Review.
-
Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.Oncogene. 2015 Jan 8;34(2):246-56. doi: 10.1038/onc.2013.535. Epub 2013 Dec 23. Oncogene. 2015. PMID: 24362533
-
The biology of cancer testis antigens: putative function, regulation and therapeutic potential.Mol Oncol. 2011 Apr;5(2):164-82. doi: 10.1016/j.molonc.2011.02.001. Epub 2011 Feb 18. Mol Oncol. 2011. PMID: 21376678 Free PMC article.
-
BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.Mol Cancer Res. 2019 Oct;17(10):2051-2062. doi: 10.1158/1541-7786.MCR-19-0310. Epub 2019 Jul 10. Mol Cancer Res. 2019. PMID: 31292201 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources